Get started
Author

Heidi Roschitzki‐Voser

Observed names: H. Roschitzki, H. Roschitzki-Voser, Heidi Roschitzki, Heidi Roschitzki-Voser, Heidi Roschitzki-voser, Roschitzki-Voser, H, Roschitzki-Voser, H., Roschitzki-Voser, Heidi
ORCID: 0000-0002-5432-2385
Observed ORCID: 0000-0002-5432-2385
OpenAlex ID: A5019129337
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
2018 · Viviana Galimberti, Bernard F Cole, et al. · The Lancet Oncology · 574
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
2019 · Sherene Loi, Anita Giobbie-Hurder, et al. · The Lancet Oncology · 470
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2020 · S. Popat, A. Curioni-Fontecedro, et al. · Annals of Oncology · 271
PDF
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial
2019 · S. Peters, E. Felip, et al. · Lung Cancer · 162
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
2019 · Rafal Dziadziuszko, Egbert F. Smit, et al. · Journal of Thoracic Oncology · 160
PDF
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
2020 · Solange Peters, Enriqueta Felip, et al. · Journal of Thoracic Oncology · 143
PDF
Inhibition of Caspase-2 by a Designed Ankyrin Repeat Protein: Specificity, Structure, and Inhibition Mechanism
2007 · Andreas Schweizer, Heidi Roschitzki-Voser, et al. · Structure · 130
PDF
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
2021 · S. Peters, J.-L. Pujol, et al. · Annals of Oncology · 125
PDF
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021 · R.A. Soo, J.-Y. Han, et al. · Annals of Oncology · 108
The Crystal Structure of Human Pyrin B30.2 Domain: Implications for Mutations Associated with Familial Mediterranean Fever
2009 · Christopher Weinert, Christian Grütter, et al. · Journal of Molecular Biology · 66
Design, construction, and characterization of a second‐generation DARPin library with reduced hydrophobicity
2013 · Markus A. Seeger, Reto Zbinden, et al. · Protein Science · 65
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2019 · S. Popat, A. Curioni-Fontecedro, et al. · Annals of Oncology · 55
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
2020 · Solange Peters, Sarah Danson, et al. · Journal of Thoracic Oncology · 52
Altering lamina assembly identifies lamina-dependent and -independent functions for A-type lamins
2015 · Monika Zwerger, Heidi Roschitzki-Voser, et al. · Journal of Cell Science · 40
PDF
Human caspases in vitro: Expression, purification and kinetic characterization
2012 · Heidi Roschitzki-Voser, Thilo Schroeder, et al. · Protein Expression and Purification · 40
Selective and Sensitive Monitoring of Caspase-1 Activity by a Novel Bioluminescent Activity-Based Probe
2010 · Maik Kindermann, Heidi Roschitzki-Voser, et al. · Chemistry & Biology · 40
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2023 · Elisabetta Munzone, Meredith M. Regan, et al. · JAMA Oncology · 38
A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
2025 · E. Felip, S. Popat, et al. · Annals of Oncology · 24
PDF
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.
2018 · Solange Peters, Dirk De Ruysscher, et al. · Journal of Clinical Oncology · 24
A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial.
2017 · Egbert F. Smit, Solange Peters, et al. · Journal of Clinical Oncology · 23
LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
2020 · S. Peters, J-L. Pujol, et al. · Annals of Oncology · 21
PDF
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
2019 · Miguel-Angel Molina-Vila, Rolf A. Stahel, et al. · Journal of Thoracic Oncology · 17
PDF
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
2024 · Sanjay Popat, Enriqueta Felip, et al. · Journal of Clinical Oncology · 13
PDF
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
2022 · U. Dafni, R.A. Soo, et al. · ESMO Open · 13
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
2025 · Sabine Schmid, Georgia Dimopoulou, et al. · Lung Cancer · 12
PDF
Works count: 75
Citation count: 3,027
H-index: 22
I10-index: 28
Year
Topic
Type